Learn all about the history of Medix Biochemica, and how our innovative solutions, along with collaborations and partnerships, help our customers develop better diagnostic tools for the in vitro diagnostic industry.
Medix Biochemica was established in Finland in 1985, and since then we have been manufacturing and supplying high-quality raw materials for the in vitro diagnostics (IVD) industry, as well as research and development institutes.
Where it all began
The origins of Medix Biochemica’s technology stem from the discovery of the hybridoma technique used for the production of monoclonal antibodies. Georges J.F. Köhler and César Milstein were awarded the Nobel Prize in 1984 for this innovation. The hybridoma technology was applied at Medix Biochemica since the early days of the discovery. One of the key contributors was a Finnish Scientist, Jim Schröder, who later became a Professor at the University of Helsinki, and a long-standing Board Member and chairman of the Board of Medix Biochemica.
Image Source: Medix Biochemica Company Presentation (2015)
“Every single day, antibodies manufactured by us enable 1 million people to get an answer to their health questions.”—Laura-Leena Kiiskinen, Vice President of Innovation and Business Development at Medix Biochemica.
We are fully committed to offering our customers the most comprehensive IVD raw materials portfolio in the industry. In order to do this, we have acquired several companies, each with its own expertise, across the IVD market.
With these acquisitions we have broadened our portfolio of critical raw materials for the IVD industry, complemented our scientific expertise, and strengthened our local presence within the respective regions.
Together, with all our partners, we now offer over 135 years of combined diagnostics expertise to our customers all over the world.
Timeline of Medix Biochemica’s acquisitions:
Image Source: https://about.medixbiochemica.com/
Medix Biochemica continues to grow
We have radically expanded our product portfolio over the past few years, now covering not only antibodies and antigens for immunodiagnostics, but also the following:
- Enzymes and master mixes for molecular diagnostics.
- Quality control raw materials from base matrices to native lipoproteins.
- Clinical chemistry enzymes.
We also offer a wide range of bio-specimens for IVD test developers. We expand over six sites globally which provide contract development, customization, and manufacturing services for diagnostic raw materials.
In addition to that, we have exceptional in-house knowledge of Polymerase chain reaction (PCR) and assay development as well as lyophilization, to cover all essential application needs in molecular diagnostics.
Our extended offering means we can provide almost any protein, bio-specimen, or base matrix that our customers may need.
Medix Biochemica solutions help customers develop better diagnostic tools for healthcare
In the past, limitations in raw material performance, detection technologies, and data analytics have set certain technical boundaries to IVD test development. However, we are now seeing exciting technology disruptions occurring at all levels, from raw materials development to result-interpretation software.
With these concurrent advances in protein modeling and engineering, sensitive detection technologies, and AI-based data analytics, disruptive innovations are inevitable.
Our core expertise in antibody and enzyme development tailored for the IVD industry’s needs ensures that our customers’ research and development teams can focus on their assay, detection platform, and analysis software development. We support them by bringing in state-of-the-art solutions to develop the raw materials for their applications. The best innovative diagnostic methods for improved patient care come through collaboration and partnering, where each partner combines their best mind and capabilities.
Medix Biochemica in action
- Antibody rescue
One of our partnering companies produced some good monoclonal antibodies for lateral flow IVD tests but their hybridoma cell lines had deteriorated (they were no longer viable or producing the antibodies). Our Research and Development team was able to rescue the DNA sequences encoding the mAbs, and they created recombinant versions of the antibodies with unaltered antigen-binding properties. This secured the supply of two high-performing mAbs for our customers.
- A newly developed recombinant antibody for immunoPET applications
Our phage display research and development group, in less than 6 months, generated a novel binding molecule for a human membrane protein identified as a marker of CAF (cancer-associated fibroblast). The newly developed recombinant antibody is currently being used in immunoPET applications.
- The Covid-19 Pandemic
Our PCR enzyme and master mix capabilities enabled clinical laboratories and test manufacturers to develop high-performing assays for SARS-CoV-2 (COVID-19) detection, without the need for sample extraction or lysis, thus saving precious hands-on time and consumables in the laboratory.
In addition, many customers found our biospecimens accrual program to be essential by allowing us to source specific disease state patient samples, allowing for streamlined test development, validation and approval.
If you would like to receive our monthly newsletter, please subscribe below to get all of our new articles delivered straight to your inbox.